Additional Infant Patient to Receive Jaguar Health's Crofelemer for ...
(PR-inside.com) Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric and adult rare IF diseases, including microvillus inclusion disease (MVID) Company plans to file NDA for crofelemer for MVID in mid-2027 to obtain F…
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


